Postgraduate School, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
BMC Res Notes. 2022 Sep 7;15(1):292. doi: 10.1186/s13104-022-06180-3.
Cases of thrombosis have been reported after administration of SARS-CoV-2 vaccines, with controversial results relating to Oxford-AstraZeneca's ChAdOx1-S. Despite such cases being rare, they still raised concerns for their involvement in coagulopathies. Anti-cardiolipin (aCL) IgG antibodies have been linked to venous and arterial thrombosis. The aim was to evaluate the concentration of aCL IgG antibodies in vaccinated and COVID-19 positive individuals using indirect ELISA and commercial sourced calibrators.
The concentration of aCL IgG antibodies was measured in the serum of COVID-19 positive (n = 37), ChAdOx1-S vaccinated (n = 37) and BioNTech Pfizer BNT162b2 vaccinated (n = 42) individuals. Samples from COVID-19 negative, unvaccinated individuals (n = 41) served as controls. The highest percentage of positivity was in the COVID-19 positive group (18.9%). Concerning vaccination, BNT162b2 had the highest percentage of positivity (11.9%) (p = 0.0037). Additionally, aCL concentrations were evaluated at different time points in both vaccinated groups (before, 3 weeks after and 3 months after the second dose). A significant difference in the levels of aCL IgG antibodies over time (p = 0.0391) was observed only in ChAdOx1-S individuals. Our study concluded that levels of aCL, after vaccination with either of the vaccines or following SARS-CoV-2 infection, were not clinically pathogenic for the risk of thrombosis.
有报道称，在接种 SARS-CoV-2 疫苗后会出现血栓病例，而牛津-阿斯利康的 ChAdOx1-S 则存在结果有争议的情况。尽管此类病例较为罕见，但它们仍然引起了人们对其是否与凝血障碍有关的关注。抗心磷脂 (aCL) IgG 抗体与静脉和动脉血栓形成有关。本研究旨在使用间接 ELISA 和商业来源的校准品评估接种疫苗和 COVID-19 阳性个体中 aCL IgG 抗体的浓度。
在 COVID-19 阳性（n=37）、ChAdOx1-S 接种（n=37）和 BioNTech Pfizer BNT162b2 接种（n=42）个体的血清中测量了 aCL IgG 抗体的浓度。COVID-19 阴性、未接种疫苗的个体（n=41）的样本作为对照。阳性率最高的是 COVID-19 阳性组（18.9%）。关于疫苗接种，BNT162b2 的阳性率最高（11.9%）（p=0.0037）。此外，还评估了两组接种者在不同时间点的 aCL 浓度（接种前、第二剂后 3 周和 3 个月）。仅在 ChAdOx1-S 个体中观察到 aCL IgG 抗体水平随时间的显著差异（p=0.0391）。本研究得出结论，无论是接种哪种疫苗还是感染 SARS-CoV-2 后，aCL 的水平都不会对血栓形成的风险产生临床致病性。
